ReviewTranslational lung cancer research2025
Metabolite biomarkers in lung cancer: unlocking the potential of body fluid analysis for early detection and prognosis-a narrative review.
Review in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in translational lung cancer research in 2025: a narrative review.Translational lung cancer research · 2026Review
- Editorial: Liquid biopsy in non-small cell lung cancer for diagnosis, treatment selection and monitoring.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Lung cancer is a leading cause of cancer-related mortality, due to delayed diagnosis and the complexity of selecting the optimal treatment method, given the genetic diversity and heterogeneity of the disease. Traditional invasive techniques, such as tissue biopsy, carry risks of severe complications and are often costly. Therefore, there is increasing interest in non-invasive alternatives, particularly liquid biopsy. This review aims to propose promising circulating metabolite biomarkers for lung cancer and their clinical applications. Methods: A PubMed search [2014-2024] was conducted, focusing on fluid-based, non-invasive samples such as blood, urine, pleural effusion, and bronchoalveolar lavage fluid. Only English-language articles relevant to lung cancer metabolomics were included. Key Content and Findings: Analysis of altered metabolites in lung cancer patients revealed significant metabolic pathway enrichments. Upregulated pathways included arginine biosynthesis and alanine, aspartate, and glutamate metabolism, while downregulated pathways involved valine, leucine, and isoleucine biosynthesis and fatty acid metabolism. Metabolite biomarker changes across multiple body fluids were identified when comparing lung cancer patients to healthy controls. In blood, choline, serine, and threonine levels were reduced, whereas tryptophan and tyrosine were elevated. Pleural effusion exhibited decreased oleic acid and ceramide, urine showed increased creatine riboside (CR) and N-acetylneuraminic acid (NANA), and bronchoalveolar lavage fluid (BALF) revealed reductions in glycine and glycerol, highlighting distinct metabolic alterations associated with lung cancer. Conclusions: Circulating metabolite biomarkers offer a promising, non-invasive approach for early lung cancer detection and personalized treatment strategies. Their accessibility and safety provide a viable alternative to invasive biopsies. Further clinical validation is essential to integrate these biomarkers into practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.